Objective-Nucleotides such as ATP, ADP, UTP, and UDP serve as proinflammatory danger signals via purinergic receptors on their release to the extracellular space by activated or dying cells. UDP binds to the purinergic receptor Y 6 (P2Y 6 ) and propagates vascular inflammation by inducing the expression of chemokines such as monocyte chemoattractant protein 1, interleukin-8, or its mouse homologsCCL1 (chemokine [C-C motif] ligand 1)/keratinocyte chemokine, CXCL2 (chemokine [C-X-C motif] ligand 2)/macrophage inflammatory protein 2, and CXCL5 (chemokine [C-X-C motif] ligand 5)/LIX, and adhesion molecules such as vascular cell adhesion molecule 1 and intercellular cell adhesion molecule 1. Thus, P2Y 6 contributes to leukocyte recruitment and inflammation in conditions such as allergic asthma or sepsis. Because atherosclerosis is a chronic inflammatory disease driven by leukocyte recruitment to the vessel wall, we hypothesized a role of P2Y 6 in atherogenesis. Approach and Results-Intraperitoneal stimulation of wild-type mice with UDP induced rolling and adhesion of leukocytes to the vessel wall as assessed by intravital microscopy. This effect was not present in P2Y 6 -deficient mice. Atherosclerotic aortas of low-density lipoprotein receptor-deficient mice consuming high-cholesterol diet for 16 weeks expressed significantly more transcripts and protein of P2Y 6 than respective controls. Finally, P2Y 6 −/− /low-density lipoprotein receptor-deficient mice consuming high-cholesterol diet for 16 weeks developed significantly smaller atherosclerotic lesions compared with P2Y 6 +/+ /low-density lipoprotein receptor-deficient mice. Bone marrow transplantation identified a crucial role of P2Y 6 on vascular resident cells, most likely endothelial cells, on leukocyte recruitment and atherogenesis. Atherosclerotic lesions of P2Y 6 -deficient mice contained fewer macrophages and fewer lipids as determined by immunohistochemistry. Mechanistically, RNA expression of vascular cell adhesion molecule 1 and interleukin-6 was decreased in these lesions and P2Y 6 -deficient macrophages took up less modified low-density lipoprotein cholesterol. 
A therosclerosis and its sequelae such as myocardial infarction, coronary heart disease, and stroke represent the leading cause of noncommunicable death worldwide. 1 Vast experimental research and clinical science led to the appreciation of atherosclerosis as a chronic inflammatory disease. [2] [3] [4] [5] [6] However, despite the knowledge of its inflammatory nature, we still lack anti-inflammatory or immune-modulatory treatment options beyond statins. 7, 8 Increasing evidences point toward an important role of extracellular nucleotides such as ATP, ADP, UTP, or UDP in cardiovascular physiology and pathophysiology, via activating purinergic P2 receptors, which can be subdivided into 2 families: (1) the G-protein-coupled P2YR (P2Y1-14) and (2) the ligand-gated ion channels P2XR (P2X1-7) receptors. [9] [10] [11] Among the P2YR subtypes, the P2Y 6 R is particularly expressed on stromal cells such as vascular endothelial cells (ECs) and epithelial cells and is almost selectively activated by UDP. However, functional expression has also been reported on various leukocytes such as human monocytes, dendritic cells, eosinophils, and neutrophils. Activation of from epithelial/ECs, monocytes, dendritic cells, eosinophils, and neutrophils, implicating a role of the P2Y 6 R in promoting the recruitment of inflammatory cells to sites of inflammation or infection. [12] [13] [14] [15] Indeed, using a murine peritonitis model, Zhang et al 16 demonstrated that P2Y 6 promotes host defense by augmenting the expression of monocyte chemoattractant protein 1 (MCP-1) and guiding monocytes to the location of infection. Besides the chemokine-driven recruitment, also a direct chemoattractant activity of the UDP-P2Y 6 R axis has been described 17 for leukocytes. Thus, stimulation of the P2Y 6 R has been implicated with chronic inflammatory diseases. Indeed, selective inhibition or knockdown of P2Y 6 R reduced all cardinal features of experimental acute and chronic allergic asthma in mice. 18 Furthermore, P2Y 6 contributes to inflammation of intestinal mucosa promoting IL-8-dependent neutrophil recruitment. 19 Pyridoxal phosphate-6-azophenyl-2′,4′-disulfonic acid, a synthetic substance blocking several purinergic receptors including P2Y 6 , P2Y 4 , P2Y 11 , and purinergic receptors X (ion channels), reduced atherosclerosis in apolipoprotein E-deficient mice suggesting that purinergic signaling is also relevant during the inflammatory processes propagating atherogenesis. 20 In the light of these data, we hypothesized that P2Y 6 plays an important role in leukocyte recruitment to the vessel wall and that its deletion may limit experimental atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
UDP Induces Leukocyte Rolling, Adhesion, and Transmigration via P2Y 6 P2Y 6 activation induces the expression of several chemokines and adhesion molecules. [12] [13] [14] 16, 18, 19 However, the role of UDP and P2Y 6 in leukocyte recruitment to the inflamed vessel wall in vivo has not been addressed to date. To examine the latter, P2Y 6 -competent mice received peritoneal injections with 200 nmol UDP. Two hours later, the visceral peritoneum was prepared and leukocyte rolling and adhesion were analyzed by intravital microscopy. Stimulation with UDP significantly induced leukocyte rolling and adhesion compared with PBS-challenged control mice. Rolling further increased after 4 hours and decreased after 6 hours, indicating a fast regulation of adhesion molecules by UDP (n≥11; P=0.002; P=0.001). Conversely, UDP-induced leukocyte rolling and adhesion to the vessel wall were comparable between P2Y 6 -deficient mice after 2, 4, and 6 hours of UDP stimulation and wild-type controls without UDP stimulation ( Figure 1A and 1B) .
Leukocyte recruitment is mediated by the interaction between ECs and leukocytes. P2Y 6 -competent and P2Y 6 -deficient mice were either reconstituted with P2Y 6 -competent or -deficient bone marrow. To test whether P2Y 6 on leukocytes or ECs is crucial for leukocyte recruitment, mice were stimulated with 200 nmol UDP and intravital microscopy was performed (n=6 per group). As shown in Figure 1C , UDPinduced leukocyte adhesion was reduced in mice with P2Y 6 -deficient ECs compared with those with P2Y 6 -competent ECs. However, rolling was only slightly affected. Thus, P2Y 6 influences expression of adhesion molecules on ECs and endothelial P2Y 6 promotes leukocyte recruitment to the inflamed vessel wall. However, P2Y 6 deficiency on hematopoietic cells does not affect leukocyte recruitment.
To test for a role of UDP-P2Y 6 axis beyond adhesion in leukocyte migration, extracellular matrix (Matrigel) was mixed with UDP or vehicle and injected subcutaneously. After 3 days, Matrigel was removed and macrophage content was determined by F4/80 staining. UDP increased macrophage migration into Matrigel of P2Y 6 -competent mice, whereas macrophage migration into Matrigel of P2Y 6 -deficient mice was not altered by UDP ( Figure 1D ). These data demonstrate a crucial role of P2Y 6 in UDP-dependent leukocyte recruitment to the endothelium.
P2Y 6 Is Expressed in Atherosclerosis
Because leukocyte recruitment to the vessel is a crucial step in atherogenesis, we hypothesized that P2Y 6 is also involved in the development of atherosclerotic lesions. To examine the expression of P2Y 6 in murine atherosclerotic lesions, low-density lipoprotein receptor-deficient (LDLR −/− ) mice consumed high-cholesterol diet to induce atherosclerosis. LDLR −/− mice consuming chow diet served as control. After 16 weeks of feeding, atherosclerotic aortic tissue expressed significantly more P2Y 6 than respective nondiseased aortic tissue (n=4; P=0.05; Figure 2A ) as assessed by quantitative real-time polymerase chain reaction. Similarly, atherosclerotic lesions in the aortic root stained more intensely for P2Y 6 than respective sections of control animals (n=4; P=0.009; Figure 2B and 2C) suggesting a role for P2Y 6 in atherosclerosis. Distribution of P2Y 6 within the atherosclerotic lesion was assessed by 3-color immunofluorescence for cell nuclei (DAPI; 4',6-diamidino-2-phenylindole), ECs (CD31), and P2Y 6 . As shown in Figure 2D and 2E, P2Y 6 -positive staining mainly colocalized with CD31-positive ECs.
P2Y 6 Deficiency Reduces Atherosclerosis
To test for a functional role of P2Y 6 in atherogenesis, P2Y 6 −/− mice were crossed with LDLR −/− mice and consumed Figure 3D ). Leukocyte count, differential blood count, total cholesterol, and triglycerides did not differ between both study groups after diet (Table) . No phenotypic differences regarding life span, reproduction, behavior, or health occurred between the study groups.
P2Y 6 Deficiency Limits Plaque Inflammation
Because certain phenotypic features of an atherosclerotic plaque such as content of inflammatory cells and lipids coincide with plaque rupture in humans, we analyzed not only mere lesion size but also plaque composition. Parallel sections of atherosclerotic lesions were stained for lipids, macrophages, smooth muscle cells, and collagen. Interestingly, plaques from Smooth muscle cells and collagen stabilize atherosclerotic lesions by protecting the necrotic core from exposure to the blood stream and thus may help to prevent plaque rupture. Both smooth muscle cells and collagen content were increased in atherosclerotic lesions from P2Y 6 -deficient mice (P=0.04 for smooth muscle cells; P=0.02 for collagen) compared with respective controls. Taken together, P2Y 6 animals develop plaques of smaller size that display features commonly associated with more favorable and stable atherosclerotic lesions in humans (Figure 4 ). 13, 18, 19, 21 To investigate the potential mechanisms of our findings that P2Y 6 deficiency limits atherogenesis, plaque inflammation, and inflammatory cell recruitment to the vessel wall, we evaluated the expression of these molecules in arterial tissue from P2Y 6 +/+ /LDLR −/− (n=5) and P2Y 6 −/− /LDLR −/− (n=4) mice after 16 weeks of high-cholesterol diet by quantitative real-time polymerase chain reaction. Expression of IL-6 and VCAM-1 was significantly reduced in P2Y 6 -deficient atherosclerotic lesions, whereas MCP-1 and ICAM-1 did not differ when compared with respective controls. KC expression tended to be decreased ( Figure 5 ). Increased VCAM-1 expression was confirmed by immunohistochemistry. These data suggest VCAM-1 expression as potential mechanism limiting leukocyte recruitment to the vessel wall and attenuating atherogenesis in P2Y 6 -deficient mice.
P2Y 6 -Deficient Macrophages Take up Less Modified LDL Cholesterol
Modified LDL cholesterol uptake and foam cell formation are key processes in atherogenesis. Atherosclerotic Before and after 16 weeks of high-cholesterol diet, blood was taken and total leukocytes and platelets were measured in thousand per microliter (tsd/μL). Furthermore, leukocyte subsets were determined by fluorescence-activated cell sorting analysis after diet. Plasma total cholesterol was measured after diet. LDLR −/− indicates low-density lipoprotein receptor deficient.
lesions from P2Y 6 -deficient mice contained significantly reduced amounts of lipids indicating a role of P2Y 6 in cellular cholesterol accumulation. Therefore, we isolated P2Y 6 -competent and -deficient macrophages and incubated them with ALEXA488-marked acetylated LDL cholesterol. Acetylated LDL cholesterol uptake was quantified by fluorescence-activated cell sorting analysis. As shown in Figure 5 , macrophages from P2Y 6 -deficient showed reduced lipid accumulation and decreased foam cell formation compared with respective controls.
Discussion
The present study reports an atheroprotective effect of P2Y 6 deficiency in mice. We show that the UDP-P2Y 6 axis induces leukocyte recruitment to the vessel wall. Accordingly, fewer macrophages accumulated in atherosclerotic lesions of P2Y 6 -deficient mice. Leukocyte migration into nascent atherosclerotic lesions is a crucial and constant event throughout atherogenesis. 2, 22 Previous studies identified extracellular nucleotides, such as ATP, ADP, UTP, and UDP, ligands of purinergic receptors, as inducers of chemokine and adhesion molecule expression.
10,23,24 Activation of P2Y 6 attracts leukocytes to sites of inflammation by promoting MCP-1, IL-8 expression in humans, and their analogs MCP-1 and KC/macrophage inflammatory protein 2/LIX in mice. 12, 16, 18, 19 Furthermore, pharmacological inhibition of P2Y 6 reduced the expression of the adhesion molecules VCAM-1 and ICAM-1 on an EC line after tumor necrosis factor-α stimulation, implicating that P2Y 6 contributes to leukocyte adhesion. 25, 26 Administration of UDP aggravates colitis-like disease by inducing neutrophil recruitment to the bowel indicating an important role of UDP and P2Y 6 in inflammation. 19 Accordingly, in bacterial peritonitis, UDP injection results in a more efficacious clearance of Escherichia coli, suggesting again a proinflammatory role of the UDP-P2Y 6 axis. 16 In the present study, we provide evidence that UDP induces leukocyte rolling on and adhesion to inflamed vessels via P2Y 6 in vivo. Leukocyte adhesion in bone marrow chimera with P2Y 6 deficiency on resident cells was markedly reduced compared with mice with P2Y 6 -competent resident cells assessed by intravital microscopy. These data suggest that endothelial P2Y 6 accounts for leukocyte recruitment in vascular inflammation.
Because UDP and P2Y 6 signaling contribute to chronic inflammatory diseases such as allergic asthma, colitis, and gout by leukocyte activation, we postulated a role of P2Y 6 in atherosclerosis.
14,18,19 P2Y 6 is overexpressed in inflamed tissue such as lipopolysaccharide-and monosodium urate-mediated inflammation. 26 Atherosclerotic lesions of apolipoprotein E-deficient mice contain more P2Y 6 mRNA compared with wild-type mice. 20 Our data confirm overexpression of P2Y 6 in atherosclerotic lesions of LDLR −/− mice consuming 16 weeks of high cholesterol both by quantitative polymerase chain reaction and immunohistochemistry. Furthermore, P2Y 6 mainly colocalized with the endothelial marker CD31. Guns et al 20 reported in a short-time atherosclerosis study that a 4-week treatment with pyridoxal phosphate-6-azophenyl-2′,4′-disulfonic acid, a broad purinergic receptor antagonist blocking P2Y 6 , P2Y 4 , P2Y 11 , and purinergic receptors X (ion channels), reduced atherosclerosis in apolipoprotein E-deficient mice. In the present study, we demonstrate that LDLR −/− mice specifically deficient in P2Y 6 developed significantly smaller atherosclerotic lesions than respective controls. Atherosclerosis was markedly reduced in mice with P2Y 6 deficiency on vascular resident cells, most likely ECs. This is in line with the recent finding in murine lung inflammation that epithelial but not hematopoietic P2Y 6 accounts for leukocyte recruitment. 18 Analysis of plaque composition revealed a decreased amount of macrophages and lipids in P2Y 6 deficient mice and a relatively increased amount of smooth muscle cells and collagen. These are features commonly associated with a more stable plaque phenotype in humans. 27 The reduced amount of lipids within the atherosclerotic plaques of P2Y 6 -deficient animals can be driven by less lesional macrophage content or disturbed foam cell formation. Beyond the role of P2Y 6 in leukocyte recruitment, we observed a reduced lipid uptake of P2Y 6 -deficient macrophages in vitro indicating a role of P2Y 6 in foam cell formation. But this might not affect plaque growth in vivo because atherosclerosis was dependent on nonhematopoietic P2Y 6 .
Based on our findings that (1) P2Y 6 -deficient mice are resistant to UDP-induced vascular inflammation and (2) atherosclerotic lesions of P2Y 6 -deficient mice contain less inflammatory cells than respective controls, we tested whether some key adhesion molecules, chemokines, and cytokines in atherosclerotic lesions are regulated by P2Y 6 using quantitative polymerase chain reaction. Interestingly, the adhesion molecule VCAM-1 was decreased in P2Y 6 -deficient atherosclerotic lesions indicating a crucial role of P2Y 6 in VCAM-1-induced leukocyte recruitment to the atherosclerotic lesion. VCAM-1 is known to be critical atherosclerotic lesion formation, whereas the role of ICAM-1 in atherosclerosis is controversially discussed. 28, 29 Although the UDP-P2Y 6 axis seems to regulate both VCAM-1 and ICAM-1 on ECs in vitro, in the present study, only the downregulation of VCAM-1 in P2Y 6 -deficient lesions likely reduces leukocyte adhesion and recruitment to the plaque. 21 Chemokines activate leukocytes and facilitate leukocyte rolling and trigger leukocyte arrest. 30 Because in allergic asthma epithelial cells drive the antiinflammatory effect of P2Y 6 deficiency, one could speculate that endothelial P2Y 6 deficiency accounts for the antiatherogenic effect by reduced endothelial VCAM-1 expression. 18 Beside its role in adhesion molecule regulation, P2Y 6 is also involved in chemokine expression by inducing MCP-1 and KC/macrophage inflammatory protein 2 in mice. 12, 21 We demonstrate a slight reduction of KC expression in P2Y 6 -deficient atherosclerotic lesions, whereas MCP-1 expression does not differ between the study groups. Furthermore, plaques of P2Y 6 -deficient mice are less inflamed because of decreased IL-6 expression, a proatherogenic cytokine. 31 Purinergic receptors are ubiquitously expressed throughout the vasculature, and thus, it is supposed that extracellular nucleotides as danger signals and their receptors participate in atherosclerosis. 32 Antagonists of ADP such as ticlopidine, clopidogrel, and ticagrelor, which block the P2Y 12 receptor on platelets, are already established in treatment of coronary heart disease. 33 Li et al 34 reported that P2Y 12 deficiency on platelets reduces atherosclerosis in mice by augmenting inflammatory cell recruitment via decreased platelet factor 4 and P-selectin expression. Deficiency of the ADP receptor P2Y 1 on ECs diminished atherosclerotic lesions and tumor necrosis factor-α-induced vascular inflammation in mice. 35, 36 In conclusion, the present study demonstrates that UDP induces leukocyte recruitment to the vessel wall via endothelial P2Y 6 receptor. Because leukocyte recruitment is a key process in atherosclerosis, P2Y 6 deficiency reduces atherosclerotic lesions in mice by decreased VCAM-1 expression. Our data suggest the UDP-P2Y 6 axis as promising potential target for prevention or treatment of vascular inflammation as seen with atherosclerosis.
